Table 4 In vitro antifungal susceptibility of 1539 clinical C. albicans and C. glabrata isolates from VVC and RVVC as determined by the CLSI method

 VVC

Range

0.15–32

0.030–128

0.03–32

0.03–256

0.008–0.5

0.008–0.5

0.008–0.5

0.015–32

0.015–32

0.06–128

0.015–32

0.015–32

0.015–32

0.015–8

GM

0.21

0.65

1.55

39.23

0.02

0.1

0.03

0.11

0.05

0.74

0.09

0.27

0.12

0.06

MIC90

0.5

4

8

256

0.03

0.25

0.25

1

0.25

4

1

4

2

0.5

 RVVC

Range

0.015–32

0.06–128

0.03–32

0.25–256

0.008–0.25

0.008–0.5

0.008–0.5

0.015–8

0.015–16

0.06–64

0.015–32

0.015–32

0.015–32

0.015–8

GM

0.25

0.94

1.82

74.50

0.01

0.1

0.03

0.13

0.05

1.03

0.10

0.46

0.33

0.09

MIC90

0.6

4

8

256

0.015

0.25

0.06

1

0.5

4

0.5

8

8

0.5

P

0.813

0.435

0.770

0

0.242

0.7

0.566

0.736

0.341

0.14

0.041

0.053

0

0.34

 VVC

Range

0.03–2

0.06–16

0.03–32

0.25–256

0.015–0.5

0.008–0.5

0.008–0.5

0.015–16

0.015–16

0.125–128

0.015–32

0.015–16

0.015–32

0.015–32

GM

0.33

0.18

3.88

40.63

0.03

0.06

0.05

0.24

0.23

1.68

0.42

0.25

0.15

0.09

MIC90

1

1

8

256

0.06

0.25

0.25

1

1

8

4

2

1

0.25

 RVVC

Range

0.03–2

0.06–2

0.03–16

0.25–256

0.008–0.06

0.008–0.5

0.008–0.5

0.015–8

0.03–4

0.125–128

0.03–32

0.03–32

0.015–32

0.015–32

GM

0.20

0.17

2.31

8.86

0.02

0.06

0.04

0.16

0.134

1.03

0.29

0.27

0.17

0.11

MIC90

0.5

1

8

256

0.03

0.25

0.25

1

1

16

2

4

2

0.5

P

0.017

0.366

0.035

0.015

0.058

0.68

0.78

0.87

0.25

0.1

1

0.043

0.683

0.293